Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on November 20, 2013 and is headquartered in Beverly Hills, CA.
Market Cap | 82.129 Million | Shares Outstanding | 24.298 Million | Avg 30-day Volume | 93.539 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | |
Price to Revenue | 408.1193 | Debt to Equity | 0.137 | EBITDA | -23.321 Million |
Price to Book Value | 3.3799 | Operating Margin | -11568.334299999999 | Enterprise Value | 28.332 Million |
Current Ratio | 4.163 | EPS Growth | 0 | Quick Ratio | 4.073 |
1 Yr BETA | 0.866 | 52-week High/Low | 6.22 / 2.56 | Profit Margin | -11117.4394 |
Operating Cash Flow Growth | 186.8535 | Altman Z-Score | -1.6175 | Free Cash Flow to Firm | 8.608 Million |
Earnings Report | 2022-08-11 |
Please sign in first
none
none
43.4 Thousand total shares from 2 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
16,595 | 2022-03-31 | 2 | |
|
9,155 | 2022-03-29 | 2 | |
|
0 | 2022-03-08 | 2 | |
|
84,080 | 2022-01-03 | 2 | |
|
359,632 | 2022-01-03 | 1 | |
MARBAN LINDA CHIEF EXECUTIVE OFFICER |
|
377,830 | 2022-01-03 | 1 |
KRASNEY KAREN EVP, GENERAL COUNSEL |
|
84,080 | 2022-01-03 | 1 |
BERGMANN ANTHONY CHIEF FINANCIAL OFFICER |
|
166,980 | 2022-01-03 | 1 |
|
7,690 | 2022-01-03 | 3 | |
ASCHEIM DEBORAH CHIEF MEDICAL OFFICER |
|
0 | 2018-07-24 | 0 |
|
0 | 2018-01-02 | 0 | |
SMITH RACHEL VICE PRESIDENT OF R&D |
|
0 | 2018-01-02 | 0 |
|
4,049,959 | 2017-05-09 | 0 | |
|
3,307,863 | 2016-12-31 | 0 | |
|
1,182,439 | 2016-03-16 | 0 | |
GERSHELL LELAND CHIEF FINANCIAL OFFICER |
|
3,150 | 2016-03-16 | 0 |
|
4,750,185 | 2016-03-16 | 0 | |
|
0 | 2015-03-03 | 0 | |
HAMER ANDREW WARWICK VP OF MEDICAL AFFAIRS |
|
0 | 2015-03-03 | 0 |
DAVIES ANTHONY CHIEF TECHNOLOGY OFFICER |
|
0 | 2013-11-20 | 0 |
|
5,047,221 | 2013-11-20 | 0 | |
HORTON DARLENE P PRESIDENT & CEO |
|
0 | 2012-08-06 | 0 |
|
2,258,327 | 2011-07-18 | 0 | |
LIEU HSIAO VP, CLINICAL RESEARCH |
|
100 | 2011-05-26 | 0 |
|
27,588 | 2011-05-10 | 0 | |
|
711,420 | 2011-05-10 | 0 | |
|
0 | 2011-05-10 | 0 | |
EVANS DARON CHIEF FINANCIAL OFFICER |
|
23,752 | 2011-04-18 | 0 |
BREWER RICHARD B EXECUTIVE CHAIRMAN |
|
0 | 2010-07-26 | 0 |
|
No longer subject to file | 2009-12-31 | 0 | |
STRUMPH PETER M CHIEF EXECUTIVE OFFICER |
|
0 | 2009-01-16 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-04-01 17:00:22 -0400 | 2022-03-31 | F | 11,309 | $3.43 | d | 16,595 | direct | -1.6129 | -5.1075 | -15.3226 | 0.0 | 1 | -22.3118 | 28 | ||
2022-04-01 17:00:22 -0400 | 2022-03-31 | M | 27,904 | $1.39 | a | 27,904 | direct | -1.6129 | -5.1075 | -15.3226 | 0.0 | 1 | -22.3118 | 28 | ||
2022-04-01 17:00:22 -0400 | 2022-03-31 | M | 15,455 | d | 0 | direct | ||||||||||
2022-04-01 17:00:22 -0400 | 2022-03-31 | M | 12,449 | d | 0 | direct | ||||||||||
2022-03-31 17:00:20 -0400 | 2022-03-29 | F | 6,300 | $3.41 | d | 9,155 | direct | 3.6212 | -2.2284 | -13.9276 | 3.6212 | 2 | -19.4986 | 29 | ||
2022-03-31 17:00:20 -0400 | 2022-03-29 | M | 15,455 | d | 0 | direct | ||||||||||
2022-03-31 17:00:20 -0400 | 2022-03-29 | M | 15,455 | $1.39 | a | 15,455 | direct | 3.6212 | -2.2284 | -13.9276 | 3.6212 | 2 | -19.4986 | 29 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 22:15:03 UTC | -5.5337 | 6.3537 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 21:45:03 UTC | -5.526 | 6.346 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 21:15:03 UTC | -5.526 | 6.346 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 20:45:03 UTC | -5.5169 | 6.3369 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 20:15:03 UTC | -5.5169 | 6.3369 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 19:45:03 UTC | -5.5169 | 6.3369 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 19:15:03 UTC | -5.5169 | 6.3369 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 18:45:04 UTC | -5.5332 | 6.3532 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 18:15:03 UTC | -5.5332 | 6.3532 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 17:45:03 UTC | -5.5332 | 6.3532 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 17:15:03 UTC | -5.5332 | 6.3532 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 16:45:04 UTC | -5.5332 | 6.3532 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 16:15:03 UTC | -5.5332 | 6.3532 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 15:45:03 UTC | -5.5332 | 6.3532 | 850000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 15:15:03 UTC | -5.5332 | 6.3532 | 750000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 14:45:03 UTC | -5.2996 | 6.1196 | 750000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 14:15:03 UTC | -5.2996 | 6.1196 | 750000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 13:45:05 UTC | -5.2996 | 6.1196 | 750000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 13:15:03 UTC | -5.2996 | 6.1196 | 700000 |
CAPRICOR THERAPEUTICS INC CAPR | 2022-05-26 12:45:03 UTC | -5.2996 | 6.1196 | 700000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | CAPR | -6100.0 shares, $-17873.0 | 2021-12-31 | N-PORT |